Filovirus Inhibitor

Porgaviximab is a monoclonal antibody that can be used Ebola infection research.

Larcaviximab (c4G7-N) is an IgG1 kappa chimeric monoclonal antibody against Ebola virus glycoprotein, which is applicable to studies related to Ebola virus infection.

Chlorphenoxamine hydrochloride, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine hydrochloride inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine hydrochloride shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with IC₅₀s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine hydrochloride is used for allergic conditions, urticaria, viral diseases and Parkinson’s disease.

EBOV/MARV-IN-2 (compound 13) is an Ebolavirus (EBOV, IC₅₀=0.9 μM) and Marburg virus (MARV, IC₅₀=2.7 μM) inhibitor.

EBOV-IN-8 (Compound 30) inhibits Ebola pseudotyped virus (pEBOV) infection with an IC₅₀ of 62.1% at 10 μM.

D011-2120 functions as an antiviral agent by inhibiting microtubule polymerization, disrupting the Golgi complex, and preventing viral trafficking to the plasma membrane during the virus egress process.

As-358 has inhibitory effects against Ebola virus and Marburg virus, with IC₅₀s of 47.5 μM and 3.7 μM.

ASN03576800 could be a potent inhibitor for Ebola virus matrix protein VP40 in process of viral assembly and budding process. ASN03576800 occupies the RNA binding region of VP40.

EBOV-IN-5 (compound 14) is an antiviral agent that inhibits Ebola virus (EBOV) infection. EBOV-IN-5 inhibits the binding of the EBOV glycoprotein EBOV-GPcl to NPC1, an indispensable host receptor required for viral fusion/entry.

K777 tosylate is a potent, orally active and irreversible cysteine protease inhibitor. K777 tosylate is also a potent CYP3A4 inhibitor with an IC₅₀ of 60 nM. K777 tosylate irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 tosylate is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 tosylate inhibits SARS-CoV and EBOV pseudovirus entry with IC₅₀ values of 0.68 nM and 0.87 nM, respectively.

EBOV/MARV-IN-3 (compound 32) is a potent EBOV and MARV inhibitor with IC₅₀ values of 0.5, 1.2 µM, respectively. EBOV/MARV-IN-3 binds to the hydrophobic pocket close to EBOV Y517. EBOV/MARV-IN-3 shows antiviral activity.

SCR007 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR007 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR007 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR007 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR007 can be used for the study and prevention of enveloped virus pandemics.

EBOV-IN-4 (compound 12), a benzothiazepine, is a potent Ebola virus (EBOV) inhibitor with 64.9% inhibitory for EBOV-GP-pseudotype virus (pEBOV) with 10 μM. EBOV-IN-4 is inactive with ASFV.

SCR005 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR005 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR005 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR005 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR005 can be used for the study and prevention of enveloped virus pandemics.

(-)-Isopinocampheol (l-Isopinocampheol) is a compound with anti-filovirus activity. Its derivatives inhibit infection by Ebola virus and Marburg virus, possibly through binding to surface glycoproteins. It also has lysosomal affinity.

As-358 (hydrochloride) has inhibitory effects against Ebola virus and Marburg virus with IC₅₀s of 9.1 μM and 18.1 μM, as well as exhibits good in vivo safety.

ASF-006 sodium, a tetrapodal tryptophan derivative, is a potent viral invasion inhibitor. ASF-006 sodium shows potent antiviral activity against different SARS-CoV-2 Omicron variants but not against the ancestral SARS-CoV.2 strain (Wuhan-Hu-1). ASF-006 sodium competitively inhibits receptor-binding domain (RBD)-ACE2 binding via an allosteric mechanism. ASF-006 sodium inhibits Omicron BA.1, Omicron XBB.1.5, respiratory syncytial virus (RSV) and Ebola virus infection with IC₅₀s of 0.02 μM, 0.3 μM, 1.52 μM and 0.2 μM, respectively. ASF-006 sodium inhibits cell entry of both HIV and enterovirus A71[1].

CP19, a histamine receptor antagonist, is an entry inhibitor against both Ebolavirus (EBOV) and Marburgvirus (MARV) with IC₅₀s of 3.4 μM and 29.5 μM, respectively. CP19 has SI values of 29.4 and 3.4 for EBOV and MARV, respectively. CP19 has antiviral activity.

EBOV-IN-3 (compound 9) is benzothiazepine compound. EBOV-IN-6 has anti-pEBOV activity with a IC₅₀ value of 0.37 μM.

EBOV-IN-9 (compound 2b) is Diphyllin derivative that blocks Ebola viral entry with an EC₅₀ of 40 nM. EBOV-IN-9 against EBOV-infected monocyte-derived macrophages with an EC₅₀ of 107 nM.